Please enable Javascript on your browser for a better experience.
The Factor XI Activity Clotting Test evaluates the functional activity of Factor XI, a key protein in the intrinsic blood coagulation pathway. By measuring how effectively Factor XI supports clot formation, this test helps clarify unexplained bleeding, abnormal aPTT results, and procedure-related clotting concerns. It provides functional insight that supports accurate diagnosis, risk assessment, and informed clinical decision-making.
The Clotting Factor VIII Activity Test measures the activity of factor VIII, a protein essential for normal blood clotting. Low activity may indicate hemophilia A or acquired deficiencies, while elevated activity is linked to clotting risk. This test helps evaluate unexplained bleeding, bruising, or thrombosis, and supports diagnosis of inherited or acquired clotting disorders, providing insight into overall hemostatic function.
The Fibrinogen Activity Test measures how well fibrinogen, a key clotting protein, helps blood form clots. Low fibrinogen may indicate excessive bleeding, liver disease, or disseminated intravascular coagulation (DIC), while high levels may signal inflammation or increased clotting risk. Doctors use this test to evaluate unexplained bleeding, monitor clotting disorders, or assess liver function. Results provide vital insight into coagulation health and treatment management.
The Factor V Leiden Mutation Analysis detects a genetic mutation in the F5 gene that increases risk of abnormal blood clotting (thrombophilia). Individuals with this mutation may be prone to deep vein thrombosis (DVT), pulmonary embolism, or pregnancy complications. Doctors use this DNA test to confirm inherited clotting disorders, assess family risk, and guide prevention strategies, including anticoagulation or lifestyle management.
The Prothrombin with INR and Partial Thromboplastin Times Test measures how long blood takes to clot by evaluating PT, INR, and aPTT. Abnormal results may indicate clotting disorders, liver disease, vitamin K deficiency, or risk of bleeding and thrombosis. Doctors use this test to monitor patients on blood thinners like warfarin, assess unexplained bleeding, and evaluate clotting function. It provides critical insight into coagulation and overall blood health.
The Activated Partial Thromboplastin Time (aPTT) Test measures how long it takes blood to clot, evaluating clotting factors and overall coagulation function. Abnormal results may indicate bleeding disorders, hemophilia, liver disease, or clotting factor deficiencies. Doctors also use this test to monitor patients on heparin therapy. Results provide essential insight into blood clotting, bleeding risk, and treatment management for safe medical care.
The Activated Protein C-Resistance Test evaluates how blood responds to activated protein C, helping identify resistance often caused by Factor V Leiden mutation. This test supports assessment of abnormal clotting, deep vein thrombosis, and inherited thrombophilia. By measuring clotting response, it provides insight into genetic risks, venous thromboembolism, and overall coagulation health.
The Prothrombin Time with INR Test measures how long it takes blood to clot and calculates the international normalized ratio (INR) for accuracy. It is commonly used to monitor patients on blood-thinning medications like warfarin and to evaluate bleeding disorders, liver disease, or vitamin K deficiency. Doctors order this test to investigate easy bruising, frequent nosebleeds, or prolonged bleeding and to ensure safe and effective anticoagulant therapy.
The von Willebrand Factor Antigen Test measures the amount of von Willebrand factor, a blood protein essential for clotting. Low levels may indicate von Willebrand disease, the most common inherited bleeding disorder, while elevated levels can occur with inflammation or pregnancy. Doctors use this test to evaluate unexplained bleeding, frequent nosebleeds, or heavy menstrual periods and to guide diagnosis and management of clotting disorders.
The Cardio IQ™ Fibrinogen Antigen Test evaluates fibrinogen concentration, a key protein that influences clotting and cardiovascular disease risk. It provides insight into vascular inflammation, atherosclerosis, and thrombotic events. This test helps identify factors that contribute to stroke, coronary artery disease, and systemic vascular complications, offering valuable information for assessing overall cardiovascular health.
The Methylenetetrahydrofolate Reductase (MTHFR) DNA Mutation Analysis detects genetic variants in the MTHFR gene that affect folate metabolism and homocysteine regulation. Mutations may increase risk for blood clots, cardiovascular disease, pregnancy complications, or certain neurological conditions. Doctors use this test to evaluate unexplained blood clotting, high homocysteine levels, or family history of related disorders.
The Alpha Fetoprotein (AFP) Tumor Marker Test measures AFP levels in blood to help detect and monitor cancers such as liver cancer, testicular cancer, and certain ovarian tumors. Elevated AFP may also be seen with liver disease, cirrhosis, or hepatitis. Doctors order this test for patients at risk of or being treated for cancer. Results provide essential insight for diagnosis, monitoring treatment response, and tracking cancer recurrence or progression.
The Plasminogen Activator Inhibitor-1 Test evaluates PAI-1 activity, a key regulator of fibrinolysis that influences clot breakdown and vascular health. Elevated levels may suggest risk for thrombosis, heart disease, or metabolic disorders. This test supports assessment of coagulation balance, cardiovascular function, and systemic conditions that affect circulation and overall metabolic health.
The D-Dimer Test measures fragments of blood clots to help detect abnormal clotting activity. Elevated levels may indicate deep vein thrombosis (DVT), pulmonary embolism (PE), or disseminated intravascular coagulation (DIC). Doctors often order this test when patients have symptoms like leg pain, chest pain, or shortness of breath. Results provide vital insight into clotting risk, helping guide diagnosis and management of thrombotic disorders.
The Hepatitis C Antibody Test with Reflex to RNA Quantitative PCR is a two-step test. The initial qualitative antibody screen detects past exposure to HCV and reports results as Reactive or Non-Reactive. If reactive, reflex PCR measures viral RNA to confirm active infection and determine viral load. Doctors use this test to diagnose hepatitis C, evaluate liver health, and guide treatment decisions, providing key information for accurate diagnosis and disease management.
The Lupus Anticoagulant Evaluation with Reflex measures PTT-LA and dRVVT to detect lupus anticoagulant antibodies, which increase risk of abnormal clotting. Reflex tests such as Hexagonal Phase Confirmation, Thrombin Clotting Time, and dRVVT mixing are performed if results are prolonged. Doctors use this panel to evaluate unexplained clotting, recurrent miscarriage, or autoimmune disease, aiding in diagnosis of antiphospholipid syndrome.
The Comprehensive Metabolic Panel (CMP) Test measures 21 markers to assess metabolic health, liver and kidney function, and electrolyte balance. It includes glucose, calcium, sodium, potassium, chloride, CO2, albumin, globulin, A/G ratio, total protein, bilirubin, ALP, AST, ALT, BUN, creatinine, BUN/creatinine ratio, and eGFR. The CMP helps detect diabetes, liver or kidney disease, and supports routine screening and chronic condition monitoring.
